Welcome to the UPF Digital Repository

Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study

Show simple item record

dc.contributor.author Guerra, Stefano
dc.contributor.author Halonen, Marilyn
dc.contributor.author Vasquez, Monica M.
dc.contributor.author Spangenberg, Amber
dc.contributor.author Stern, Debra A.
dc.contributor.author Morgan, Wayne J.
dc.contributor.author Wright, Anne L.
dc.contributor.author Carsin, Anne-Elie
dc.contributor.author Dobaño, Carlota
dc.contributor.author Barreiro Portela, Esther
dc.contributor.author Zock, Jan-Paul
dc.contributor.author Martínez-Moratalla, Jesús
dc.contributor.author Sunyer Deu, Jordi
dc.contributor.author Antó i Boqué, Josep Maria
dc.contributor.author Martinez, Fernando D.
dc.date.accessioned 2018-12-13T08:54:53Z
dc.date.available 2018-12-13T08:54:53Z
dc.date.issued 2015
dc.identifier.citation Guerra S, Halonen M, Vasquez MM, Spangenberg A, Stern DA, Morgan WJ et al. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study. Lancet Respir Med. 2015 Aug; 3(8): 613-20. DOI: 10.1016/S2213-2600(15)00196-4
dc.identifier.issn 2213-2600
dc.identifier.uri http://hdl.handle.net/10230/36054
dc.description.abstract BACKGROUND: Low concentrations of the anti-inflammatory protein CC16 (approved symbol SCGB1A1) in serum have been associated with accelerated decline in forced expiratory volume in 1 s (FEV1) in patients with chronic obstructive pulmonary disease (COPD). We investigated whether low circulating CC16 concentrations precede lung function deficits and incidence of COPD in the general population. METHODS: We assessed longitudinal data on CC16 concentrations in serum and associations with decline in FEV1 and incidence of airflow limitation for adults who were free from COPD at baseline in the population-based Tucson Epidemiological Study of Airway Obstructive Disease ([TESAOD] n=960, mean follow-up 14 years), European Community Respiratory Health Survey ([ECRHS-Sp] n=514, 11 years), and Swiss Cohort Study on Air Pollution and Lung Diseases in Adults ([SAPALDIA] n=167, 8 years) studies. Additionally, we measured circulating CC16 concentrations in samples from children aged 4-6 years in the Tucson Children's Respiratory Study (n=427), UK Manchester Asthma and Allergy Study (n=481), and the Swedish Barn/children, Allergy, Milieu, Stockholm, Epidemiological survey (n=231) birth cohorts to assess whether low CC16 concentrations in childhood were predictive for subsequent lung function. FINDINGS: After adjustment for sex, age, height, smoking status and intensity, pack-years, asthma, and FEV1 at baseline, we found an inverse association between CC16 concentration and decline in FEV1 in adults in TESAOD (4·4 mL/year additional FEV1 decline for each SD decrease in baseline CC16 concentration, p=0·0014) and ECRHS-Sp (2·4 mL/year, p=0·023); the effect in SAPALDIA was marginal (4·5 mL/year, p=0·052). Low CC16 concentration at baseline was also associated with increased risk of incident stage 2 airflow limitation (ratio of FEV1 to forced expiratory volume [FEV1/FVC] less than 70% plus FEV1 % predicted less than 80%) in TESAOD and ECRHS-Sp. In children, the lowest tertile of CC16 concentrations was associated with a subsequent FEV1 deficit of 68 mL up to age 16 years (p=0·0001), which was confirmed in children who had never smoked by age 16 years (-71 mL, p<0·0001). INTERPRETATION: Low concentrations of CC16 in serum are associated with reduced lung function in childhood, accelerated lung function decline in adulthood, and development of moderate airflow limitation in the general adult population. FUNDING: National Heart, Lung, and Blood Institute and European Union Seventh Framework Programme.
dc.description.sponsorship This study was supported by awards HL107188, HL095021, and HL056177 from the National Heart, Lung, and Blood Institute, US National Institutes of Health; FIS award PS09/01354 from the Spanish Instituto de Salud Carlos III; a post-doctoral fellowship to IL by the Environment and Health Fund, Israel; grant 33CSCO-134276 from the Swiss National Science Foundation; grant awards by the Swedish Research Council, the Swedish Heart-Lung Foundation, and the Stockholm County Council (ALF); grants G0601361 and MR/K002449/1 by the Medical Research Council, UK; a grant award by the JP Moulton Charitable Foundation; and grant agreement number 261357 (Mechanisms of the Development of ALLergy – MeDALL) by the EU Seventh Framework Programme
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Elsevier
dc.rights © Elsevier http://dx.doi.org/10.1016/S2213-2600(15)00196-4
dc.subject.other Pulmons -- Malalties obstructives
dc.subject.other Uteroglobina
dc.title Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1016/S2213-2600
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/261357
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/acceptedVersion

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking